A Big Year In Device Deals
Given the large number of high profile deals, last year felt like a big year in the device industry, but the impression left by this handful of big and big-name deals is misleading. A chart illustrating dollar volumes in acquisitions shows a major increase in 1994, however the bulk of the value is several large consolidations—Tyco buying Kendall, for example.
You may also be interested in...
The long era of suffering and lack of exits from medical device investments is finally over. For three straight years, public investors and strategic acquirers have shown a insatiable appetite for medical device companies with products and revenue. A panel of experts speaking at Windhover's recent audio conference Find the Right Exit: What Public Markets and Strategic Acquirers Will Offer in 2007 say the good times show no signs of ending, although risks do exist.
In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.